LAMEA Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024

List of Tables

The Latin America, Middle East and Africa Diabetic Neuropathy Treatment Market would witness market growth of 9.6% CAGR during the forecast period (2024-2031).

The Brazil market dominated the LAMEA Diabetic Neuropathy Treatment Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $165 million by 2031.The Argentina market is showcasing a CAGR of 10.2% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 9.3% during (2024 - 2031).

Diabetic neuropathy is a serious and debilitating complication of diabetes, affecting millions of people. It is distinguished by nerve damage induced by extended exposure to hyperglycemia. In particular, the hands and feet may experience numbness, pain, and weakness due to this condition.

Moreover, by increasing the likelihood of complications like foot ulcers and amputations and making it challenging to perform daily tasks, diabetic neuropathy can have a substantial negative effect on an individual's quality of life.

Similarly, with more individuals affected by diabetes and at risk of developing diabetic neuropathy, there is a heightened demand for this within Saudi Arabia. According to the International Diabetes Federation, 537 million people have diabetes and 73 million people in the MENA (Middle Esat and North Africa) region by 2045. This will rise to 135.7 million. In 2021, out of a total adult population of 24,194,300 in Saudi Arabia, there were approximately 4,274,100 cases of diabetes in adults, representing a prevalence rate of 17.7%.

Based on Distribution Channel, the market is segmented into Hospitals Pharmacies, Retail Pharmacies and Others. Based on Drug Class, the market is segmented into Non-Steroidal Anti-inflammatory Drugs (NSAIDs), Antidepressants, Opioid, Capsaicin and Others. Based on Disorder Type, the market is segmented into Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy and Focal Neuropathy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

List of Key Companies Profiled

Abbott Laboratories
Eli Lilly And Company
Pfizer, Inc.
Lupin Limited
Astellas Pharma, Inc.
Glenmark Pharmaceuticals Limited
Boehringer Ingelheim International GmbH
Novartis AG
McKesson Corporation
GlaxoSmithKline PLC (GSK)

LAMEA Diabetic Neuropathy Treatment Market Report Segmentation

By Distribution Channel

Hospitals Pharmacies
Retail Pharmacies
Others

By Drug Class

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
Antidepressants
Opioid
Capsaicin
Others

By Disorder Type

Peripheral Neuropathy
Autonomic Neuropathy
Proximal Neuropathy
Focal Neuropathy

By Country

Brazil
Argentina
UAE
Saudi Arabia
South Africa
Nigeria
Rest of LAMEA

Chapter 1.Market Scope & Methodology

1.1Market Definition
1.2Objectives
1.3Market Scope
1.4Segmentation
- 1.4.1LAMEA Diabetic Neuropathy Treatment Market, by Distribution Channel
- 1.4.2LAMEA Diabetic Neuropathy Treatment Market, by Drug Class
- 1.4.3LAMEA Diabetic Neuropathy Treatment Market, by Disorder Type
- 1.4.4LAMEA Diabetic Neuropathy Treatment Market, by Country
1.5Methodology for the research

Chapter 2.Market at a Glance

2.1Key Highlights

Chapter 3.Market Overview

3.1Introduction
- 3.1.1Overview
  - 3.1.1.1Market Composition and Scenario
3.2Key Factors Impacting the Market
- 3.2.1Market Drivers
- 3.2.2Market Restraints
- 3.2.3Market Opportunities
- 3.2.4Market Challenges
3.3Porter Five Forces Analysis

Chapter 4.LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel

4.1LAMEA Hospitals Pharmacies Market by Country
4.2LAMEA Retail Pharmacies Market by Country
4.3LAMEA Others Market by Country

Chapter 5.LAMEA Diabetic Neuropathy Treatment Market by Drug Class

5.1LAMEA Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country
5.2LAMEA Antidepressants Market by Country
5.3LAMEA Opioid Market by Country
5.4LAMEA Capsaicin Market by Country
5.5LAMEA Others Market by Country

Chapter 6.LAMEA Diabetic Neuropathy Treatment Market by Disorder Type

6.1LAMEA Peripheral Neuropathy Market by Country
6.2LAMEA Autonomic Neuropathy Market by Country
6.3LAMEA Proximal Neuropathy Market by Country
6.4LAMEA Focal Neuropathy Market by Country

Chapter 7.LAMEA Diabetic Neuropathy Treatment Market by Country

7.1Brazil Diabetic Neuropathy Treatment Market
- 7.1.1Brazil Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.1.2Brazil Diabetic Neuropathy Treatment Market by Drug Class
- 7.1.3Brazil Diabetic Neuropathy Treatment Market by Disorder Type
7.2Argentina Diabetic Neuropathy Treatment Market
- 7.2.1Argentina Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.2.2Argentina Diabetic Neuropathy Treatment Market by Drug Class
- 7.2.3Argentina Diabetic Neuropathy Treatment Market by Disorder Type
7.3UAE Diabetic Neuropathy Treatment Market
- 7.3.1UAE Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.3.2UAE Diabetic Neuropathy Treatment Market by Drug Class
- 7.3.3UAE Diabetic Neuropathy Treatment Market by Disorder Type
7.4Saudi Arabia Diabetic Neuropathy Treatment Market
- 7.4.1Saudi Arabia Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.4.2Saudi Arabia Diabetic Neuropathy Treatment Market by Drug Class
- 7.4.3Saudi Arabia Diabetic Neuropathy Treatment Market by Disorder Type
7.5South Africa Diabetic Neuropathy Treatment Market
- 7.5.1South Africa Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.5.2South Africa Diabetic Neuropathy Treatment Market by Drug Class
- 7.5.3South Africa Diabetic Neuropathy Treatment Market by Disorder Type
7.6Nigeria Diabetic Neuropathy Treatment Market
- 7.6.1Nigeria Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.6.2Nigeria Diabetic Neuropathy Treatment Market by Drug Class
- 7.6.3Nigeria Diabetic Neuropathy Treatment Market by Disorder Type
7.7Rest of LAMEA Diabetic Neuropathy Treatment Market
- 7.7.1Rest of LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel
- 7.7.2Rest of LAMEA Diabetic Neuropathy Treatment Market by Drug Class
- 7.7.3Rest of LAMEA Diabetic Neuropathy Treatment Market by Disorder Type

Chapter 8.Company Profiles

8.1Abbott Laboratories
- 8.1.1Company Overview
- 8.1.2Financial Analysis
- 8.1.3Segmental and Regional Analysis
- 8.1.4Research & Development Expense
- 8.1.5Recent strategies and developments:
  - 8.1.5.1Acquisition and Mergers:
  - 8.1.5.2Trial and Approval:
- 8.1.6SWOT Analysis
8.2Eli Lilly And Company
- 8.2.1Company Overview
- 8.2.2Financial Analysis
- 8.2.3Regional Analysis
- 8.2.4Research & Development Expenses
- 8.2.5Recent strategies and developments:
  - 8.2.5.1Acquisition and Mergers:
- 8.2.6SWOT Analysis
8.3Pfizer, Inc.
- 8.3.1Company Overview
- 8.3.2Financial Analysis
- 8.3.3Regional & Segmental Analysis
- 8.3.4Research & Development Expense
- 8.3.5SWOT Analysis
8.4Lupin Limited
- 8.4.1Company Overview
- 8.4.2Financial Analysis
- 8.4.3Regional Analysis
- 8.4.4Research & Development Expense
- 8.4.5SWOT Analysis
8.5Astellas Pharma, Inc.
- 8.5.1Company Overview
- 8.5.2Financial Analysis
- 8.5.3Regional Analysis
- 8.5.4Research & Development Expense
- 8.5.5SWOT Analysis
8.6Glenmark Pharmaceuticals Limited
- 8.6.1Company Overview
- 8.6.2Financial Analysis
- 8.6.3Regional Analysis
- 8.6.4Research & Development Expenses
- 8.6.5SWOT Analysis
8.7Boehringer Ingelheim International GmbH
- 8.7.1Company Overview
- 8.7.2Financial Analysis
- 8.7.3Regional & Segmental Analysis
- 8.7.4Research & Development Expenses
- 8.7.5SWOT Analysis
8.8Novartis AG
- 8.8.1Company Overview
- 8.8.2Financial Analysis
- 8.8.3Segmental and Regional Analysis
- 8.8.4Research & Development Expense
- 8.8.5Recent strategies and developments:
  - 8.8.5.1Acquisition and Mergers:
- 8.8.6SWOT Analysis
8.9McKesson Corporation
- 8.9.1Company Overview
- 8.9.2Financial Analysis
- 8.9.3Segmental Analysis
- 8.9.4Research & Development Expense
- 8.9.5SWOT Analysis
8.10.GlaxoSmithKline PLC (GSK)
- 8.10.1Company Overview
- 8.10.2Financial Analysis
- 8.10.3Regional Analysis
- 8.10.4Research & Development Expense
- 8.10.5SWOT Analysis

LIST OF TABLES

TABLE 1LAMEA Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 2LAMEA Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 3LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 4LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 5LAMEA Hospitals Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 6LAMEA Hospitals Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 7LAMEA Retail Pharmacies Market by Country, 2020 - 2023, USD Million
TABLE 8LAMEA Retail Pharmacies Market by Country, 2024 - 2031, USD Million
TABLE 9LAMEA Others Market by Country, 2020 - 2023, USD Million
TABLE 10LAMEA Others Market by Country, 2024 - 2031, USD Million
TABLE 11LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 12LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 13LAMEA Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2020 - 2023, USD Million
TABLE 14LAMEA Non-Steroidal Anti-inflammatory Drugs (NSAIDs) Market by Country, 2024 - 2031, USD Million
TABLE 15LAMEA Antidepressants Market by Country, 2020 - 2023, USD Million
TABLE 16LAMEA Antidepressants Market by Country, 2024 - 2031, USD Million
TABLE 17LAMEA Opioid Market by Country, 2020 - 2023, USD Million
TABLE 18LAMEA Opioid Market by Country, 2024 - 2031, USD Million
TABLE 19LAMEA Capsaicin Market by Country, 2020 - 2023, USD Million
TABLE 20LAMEA Capsaicin Market by Country, 2024 - 2031, USD Million
TABLE 21LAMEA Others Market by Country, 2020 - 2023, USD Million
TABLE 22LAMEA Others Market by Country, 2024 - 2031, USD Million
TABLE 23LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 24LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 25LAMEA Peripheral Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 26LAMEA Peripheral Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 27LAMEA Autonomic Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 28LAMEA Autonomic Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 29LAMEA Proximal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 30LAMEA Proximal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 31LAMEA Focal Neuropathy Market by Country, 2020 - 2023, USD Million
TABLE 32LAMEA Focal Neuropathy Market by Country, 2024 - 2031, USD Million
TABLE 33LAMEA Diabetic Neuropathy Treatment Market by Country, 2020 - 2023, USD Million
TABLE 34LAMEA Diabetic Neuropathy Treatment Market by Country, 2024 - 2031, USD Million
TABLE 35Brazil Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 36Brazil Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 37Brazil Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 38Brazil Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 39Brazil Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 40Brazil Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 41Brazil Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 42Brazil Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 43Argentina Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 44Argentina Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 45Argentina Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 46Argentina Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 47Argentina Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 48Argentina Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 49Argentina Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 50Argentina Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 51UAE Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 52UAE Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 53UAE Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 54UAE Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 55UAE Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 56UAE Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 57UAE Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 58UAE Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 59Saudi Arabia Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 60Saudi Arabia Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 61Saudi Arabia Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 62Saudi Arabia Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 63Saudi Arabia Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 64Saudi Arabia Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 65Saudi Arabia Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 66Saudi Arabia Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 67South Africa Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 68South Africa Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 69South Africa Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 70South Africa Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 71South Africa Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 72South Africa Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 73South Africa Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 74South Africa Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 75Nigeria Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 76Nigeria Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 77Nigeria Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 78Nigeria Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 79Nigeria Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 80Nigeria Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 81Nigeria Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 82Nigeria Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 83Rest of LAMEA Diabetic Neuropathy Treatment Market, 2020 - 2023, USD Million
TABLE 84Rest of LAMEA Diabetic Neuropathy Treatment Market, 2024 - 2031, USD Million
TABLE 85Rest of LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2020 - 2023, USD Million
TABLE 86Rest of LAMEA Diabetic Neuropathy Treatment Market by Distribution Channel, 2024 - 2031, USD Million
TABLE 87Rest of LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2020 - 2023, USD Million
TABLE 88Rest of LAMEA Diabetic Neuropathy Treatment Market by Drug Class, 2024 - 2031, USD Million
TABLE 89Rest of LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2020 - 2023, USD Million
TABLE 90Rest of LAMEA Diabetic Neuropathy Treatment Market by Disorder Type, 2024 - 2031, USD Million
TABLE 91Key Information - Abbott Laboratories
TABLE 92Key Information - Eli Lilly And Company
TABLE 93Key Information - Pfizer, Inc.
TABLE 94Key Information - Lupin Limited
TABLE 95key information - Astellas Pharma, Inc.
TABLE 96Key Information - Glenmark Pharmaceuticals Limited
TABLE 97Key Information - Boehringer Ingelheim International GmbH
TABLE 98Key Information - Novartis AG
TABLE 99Key Information - McKesson Corporation
TABLE 100Key Information - GlaxoSmithKline PLC

LAMEA Diabetic Neuropathy Treatment Market Size, Share & Trends Analysis Report By Distribution Channel, By Drug Class, By Disorder Type, By Country and Growth Forecast, 2024 - 2031

Description

Table of Contents